Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA has blessed the nasal spray to be used as a monotherapy for major depressive disorder. More: Johnson & Johnson's
read more
Preclinical data highlights potential in treating Alzheimer’s disease More: AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025 Source: News
read more
Combination therapy shows superior survival benefit over standard treatment More: EC approves lazertinib in combination with amivantamab for NSCLC patients Source: News
read moreLeo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure the rights to promote and sell the PD-1 inhibitor in its home region. More: Leo bags EU rights to Junshi's Loqtorzi,
read moreAn observational study from Washington University in St. Louis has shed more light on the benefits—as well as the risks—of using new diabetes and weight loss drugs from Novo Nordisk and Eli Lilly. According to the study, researchers found that
read moreThe FDA has slapped a warning letter on Sanofi’s Genzyme facility in Framingham, Massachusetts, after an inspection last summer uncovered issues around subpar manufacturing error investigations, inconsistent active pharmaceutical ingredient production, improper equipment and more. More: Sanofi API plant hit
read more© 1994 - 2026 B.M. Pharmaceuticals